view article

Figure 1
Biological activity of recombinant hC5a-derived anaphylatoxins. (a) Amino-acid sequence of the C-termini of hC5a, hC5a-desArg and hC5a-A8. The positions of the glycosylated Asn (star) and of the residue conditioning the agonist/antagonist shift for C5a proteins (triangle) are indicated. (b) Elution profile of recombinant hC5a (blue), hC5a-desArg (red) and hC5a-A8 (grey) on the SOURCE 15S column. (c) GARA for recombinant hC5a, hC5a-desArg and hC5a-A8 on stably transfected RBL cells expressing hC5aR and comparison with commercially available hC5a. All results are indicated as the means ± standard deviation of at least eight individual experiments (except for hC5a-A8, where n = 4). The NAG release activity is expressed as a percentage of the maximal NAG release activity obtained with commercially available recombinant hC5a. (d) EC50 and maximal NAG release activity observed for all proteins upon incubation with hC5aR-expressing RBL cells.

Journal logoBIOLOGICAL
CRYSTALLOGRAPHY
ISSN: 1399-0047
Follow Acta Cryst. D
Sign up for e-alerts
Follow Acta Cryst. on Twitter
Follow us on facebook
Sign up for RSS feeds